Home
VVOS
VVOS News

Latest Vivos Therapeutics Inc. (VVOS) News on June 28, 2025

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

GlobeNewswire

2 days ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

GlobeNewswire

17 days ago

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

MT Newswires

a month ago

Vivos Issues $1.1 Million Convertible Promissory Note

GuruFocus.com

a month ago

Vivos Therapeutics Inc (VVOS) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and FDA ...

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates

Zacks

a month ago

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates

Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

GlobeNewswire

a month ago

Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

GlobeNewswire

a month ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks

2 months ago

Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

MT Newswires

2 months ago

Vivos Therapeutics to Acquire The Sleep Center of Nevada

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

GlobeNewswire

2 months ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

GuruFocus.com

3 months ago

Vivos Therapeutics Inc (VVOS) Q4 2024 Earnings Call Highlights: Strategic Shifts Propel Revenue ...

Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

3 months ago

Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

Zacks

3 months ago

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

GlobeNewswire

3 months ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

GlobeNewswire

3 months ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide

GlobeNewswire

4 months ago

Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide

Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.

GlobeNewswire

4 months ago

Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.

Best Momentum Stocks to Buy for January 8th

Zacks

6 months ago

Best Momentum Stocks to Buy for January 8th

MT Newswires

6 months ago

Vivos Therapeutics Launches $3.5 Million Registered Direct Offering

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

6 months ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

Zacks

6 months ago

All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

7 months ago

Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

GuruFocus.com

7 months ago

Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

GlobeNewswire

7 months ago

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

GlobeNewswire

7 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

GlobeNewswire

9 months ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

MT Newswires

9 months ago

Vivos Therapeutics Prices $4.3 Million Common Stock Offering; Shares Fall Pre-Bell

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

9 months ago

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

MT Newswires

9 months ago

Sector Update: Health Care

MT Newswires

9 months ago

Update: Vivos Therapeutics' Shares Jump After FDA Clears Sleep Disorder Treatment Device

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

Benzinga

9 months ago

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

MT Newswires

9 months ago

Vivos Therapeutics' Sleep Disorder Treatment Device Receives FDA Clearance

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

GlobeNewswire

9 months ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

GlobeNewswire

10 months ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

GlobeNewswire

10 months ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

MT Newswires

a year ago

Vivos Therapeutics Files Registration Statement for Secondary Sale of Securities

Vivos eyes human trials for radiation treatment gel with IDE submission

Clinical Trials Arena

a year ago

Vivos eyes human trials for radiation treatment gel with IDE submission

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

GlobeNewswire

a year ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

GlobeNewswire

a year ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Bayhorse Silver Underground Drill Program Assay Results - New Mineralized Zone Identified

Newsfile

a year ago

Bayhorse Silver Underground Drill Program Assay Results - New Mineralized Zone Identified

CloudPay Launches In-App Mobile Payslip Functionality to Enhance Employee Pay Experience

Business Wire

a year ago

CloudPay Launches In-App Mobile Payslip Functionality to Enhance Employee Pay Experience

How often should you change your banking passwords, really?

Yahoo Personal Finance

a year ago

How often should you change your banking passwords, really?

Nvidia begins trading Monday after 10-for-1 stock split

Yahoo Finance

a year ago

Nvidia begins trading Monday after 10-for-1 stock split

Biden's team asks CEOs how to further boost the economy while Trump says business is on his side

Associated Press Finance

a year ago

Biden's team asks CEOs how to further boost the economy while Trump says business is on his side

Ulta Beauty: A Debt-Free, Growing Business With Upside Potential

GuruFocus.com

a year ago

Ulta Beauty: A Debt-Free, Growing Business With Upside Potential

Costco's Upside Is Limited Due to Valuation

GuruFocus.com

a year ago

Costco's Upside Is Limited Due to Valuation

Landolt Space Mission: resolving astronomical-calibration problems

CNW Group

a year ago

Landolt Space Mission: resolving astronomical-calibration problems

Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified Directors

GlobeNewswire

a year ago

Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified Directors

GuruFocus.com

a year ago

Vivos Therapeutics Inc (VVOS) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

GlobeNewswire

a year ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

GlobeNewswire

a year ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices

News Direct

a year ago

Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

GlobeNewswire

a year ago

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript

Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

a year ago

Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

GlobeNewswire

a year ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

GlobeNewswire

a year ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

3 Stocks to Turn $1,000 Into $1 Million: February 2024

InvestorPlace

a year ago

3 Stocks to Turn $1,000 Into $1 Million: February 2024

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds

GlobeNewswire

a year ago

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds

Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions

News Direct

a year ago

Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

GlobeNewswire

a year ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Credit Acceptance (CACC) Q4 Earnings and Revenues Top Estimates

Zacks

a year ago

Credit Acceptance (CACC) Q4 Earnings and Revenues Top Estimates

$MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

GlobeNewswire

a year ago

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

CURO to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 7, 2024

Business Wire

a year ago

CURO to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 7, 2024

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GlobeNewswire

a year ago

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

AgEagle Aerial Systems Appoints Chairman Grant Begley as Interim CEO

GlobeNewswire

a year ago

AgEagle Aerial Systems Appoints Chairman Grant Begley as Interim CEO

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results

GlobeNewswire

a year ago

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results

Increasing losses over year doesn't faze Generation Income Properties (NASDAQ:GIPR) investors as stock jumps 12% this past week

Simply Wall St.

a year ago

Increasing losses over year doesn't faze Generation Income Properties (NASDAQ:GIPR) investors as stock jumps 12% this past week

Foresight CEO Letter to Shareholders

GlobeNewswire

a year ago

Foresight CEO Letter to Shareholders

Addex to Present at the Swiss Equities Baader Conference

GlobeNewswire

a year ago

Addex to Present at the Swiss Equities Baader Conference

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA

GlobeNewswire

a year ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA

Zacks Industry Outlook Highlights Dorian LPG, EuroDry and Kirby

Zacks

a year ago

Zacks Industry Outlook Highlights Dorian LPG, EuroDry and Kirby

Addex to Present at Biotech Showcase™ 2024

GlobeNewswire

a year ago

Addex to Present at Biotech Showcase™ 2024

3 Impressive Shipping Stocks Worth Betting on in 2024

Zacks

a year ago

3 Impressive Shipping Stocks Worth Betting on in 2024

Ceragon Networks to Participate in the Needham Growth Conference

PR Newswire

a year ago

Ceragon Networks to Participate in the Needham Growth Conference

Analysts Expect Breakeven For Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Before Long

Simply Wall St.

a year ago

Analysts Expect Breakeven For Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Before Long

Linkage Global Inc Announces Closing of $6,000,000 Initial Public Offering

GlobeNewswire

2 years ago

Linkage Global Inc Announces Closing of $6,000,000 Initial Public Offering

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc

GuruFocus.com

2 years ago

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc

Shareholders Should Be Pleased With Avino Silver & Gold Mines Ltd.'s (TSE:ASM) Price

Simply Wall St.

2 years ago

Shareholders Should Be Pleased With Avino Silver & Gold Mines Ltd.'s (TSE:ASM) Price

Presto Announces Stanford PhD and AI technologist Debarag Banerjee as Head of Voice Engineering

GlobeNewswire

2 years ago

Presto Announces Stanford PhD and AI technologist Debarag Banerjee as Head of Voice Engineering

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

GlobeNewswire

2 years ago

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

GlobeNewswire

2 years ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

GlobeNewswire

2 years ago

Kaixin Auto Holdings Announces Establishing AI Automobile Research Institute to Formulate AI Development Strategy

36Kr Holdings Inc. (NASDAQ:KRKR) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

36Kr Holdings Inc. (NASDAQ:KRKR) Q3 2023 Earnings Call Transcript

Secure Medical Chooses Edgio for Fast, Secure Delivery of Telehealth Services

Business Wire

2 years ago

Secure Medical Chooses Edgio for Fast, Secure Delivery of Telehealth Services

Webuy Global Limited Reports 62% Increase in Revenue to $24.4 Million for the First Half of 2023

GlobeNewswire

2 years ago

Webuy Global Limited Reports 62% Increase in Revenue to $24.4 Million for the First Half of 2023

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

PR Newswire

2 years ago

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Vivos receives FDA 510(k) clearance for oral devices to treat severe sleep apnea

MedTech Dive

2 years ago

Vivos receives FDA 510(k) clearance for oral devices to treat severe sleep apnea

News Direct

2 years ago

Vivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apnea

Reuters

2 years ago

UPDATE 2-US FDA clears Vivos Therapeutics' oral device for sleep apnea

Reuters

2 years ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

GlobeNewswire

2 years ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Business Wire

2 years ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

TOP Ships Inc. Announces Extension of Time Charter Employment for Two VLCC Tankers

GlobeNewswire

2 years ago

TOP Ships Inc. Announces Extension of Time Charter Employment for Two VLCC Tankers

GlobeNewswire

2 years ago

Kaixin Auto Holdings Announces Supplements to Unaudited First Half 2023 Financial Results

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire

2 years ago

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

Tomi Environmental Solutions, Inc. Reports Third Quarter Financial Results

GlobeNewswire

2 years ago

Tomi Environmental Solutions, Inc. Reports Third Quarter Financial Results

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Business Wire

2 years ago

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

GlobeNewswire

2 years ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

AGBA Group Releases Third Quarter 2023 Financial Results

GlobeNewswire

2 years ago

AGBA Group Releases Third Quarter 2023 Financial Results

Share on Social Networks: